Literature DB >> 21959345

Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes.

Alain G Bertoni1, Lynne E Wagenknecht, Dalane W Kitzman, Santica M Marcovina, Julia T Rushing, Mark A Espeland.   

Abstract

Look AHEAD (Action for Health in Diabetes) is a randomized trial determining whether intensive lifestyle intervention (ILI) aimed at long-term weight loss and increased physical fitness reduces cardiovascular morbidity and mortality in overweight and obese individuals with type 2 diabetes compared to control (diabetes support and education, DSE). We investigated the correlates of N-terminal pro-brain natriuretic peptide (NT-proBNP), a biomarker associated with heart failure (HF) risk, in a subsample from 15 of 16 participating centers and tested the hypothesis that ILI decreased NT-proBNP levels. Baseline and 1-year blood samples were assayed for NT-proBNP in a random sample of 1,500 without, and all 628 with, self-reported baseline CVD (cardiovascular disease) (N = 2,128). Linear models were used to assess relationships that log-transformed NT-proBNP had with CVD risk factors at baseline and that 1-year changes in NT-proBNP had with intervention assignment. At baseline, the mean (s.d.) age, BMI, and hemoglobin A(1c) (HbA(1c)) were 59.6 (6.8) years, 36.0 kg/m(2) (5.8), and 7.2% (1.1), respectively. Baseline geometric mean NT-proBNP was not different by condition (ILI 53.3 vs. DSE 51.5, P = 0.45), was not associated with BMI, and was inversely associated with HbA(1c). At 1 year, ILI participants achieved an average weight loss of 8.3% compared to 0.7% in DSE. At 1 year, NT-proBNP levels increased to a greater extent in the intervention arm (ILI +21.3% vs. DSE +14.2%, P = 0.046). The increased NT-proBNP associated with ILI was correlated with changes in HbA(1c), BMI, and body composition. In conclusion, among overweight and obese persons with diabetes, an ILI that reduced weight was associated with an increased NT-proBNP.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21959345      PMCID: PMC3509930          DOI: 10.1038/oby.2011.296

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  42 in total

1.  Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria.

Authors:  P Gaede; P Hildebrandt; G Hess; H-H Parving; O Pedersen
Journal:  Diabetologia       Date:  2004-12-24       Impact factor: 10.122

2.  Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study.

Authors:  Sandeep R Das; Mark H Drazner; Daniel L Dries; Gloria L Vega; Harold G Stanek; Shuaib M Abdullah; Russell M Canham; Anne K Chung; David Leonard; Frank H Wians; James A de Lemos
Journal:  Circulation       Date:  2005-10-04       Impact factor: 29.690

3.  How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study.

Authors:  Lori B Daniels; Paul Clopton; Vikas Bhalla; Padma Krishnaswamy; Richard M Nowak; James McCord; Judd E Hollander; Philippe Duc; Torbjørn Omland; Alan B Storrow; William T Abraham; Alan H B Wu; Philippe G Steg; Arne Westheim; Cathrine Wold Knudsen; Alberto Perez; Radmila Kazanegra; Howard C Herrmann; Peter A McCullough; Alan S Maisel
Journal:  Am Heart J       Date:  2006-05       Impact factor: 4.749

4.  Sulfonylurea therapy is associated with increased NT-proBNP levels in the treatment of type 2 diabetes.

Authors:  Hugh D Tildesley; Cristina M Aydin; Andrew Ignaszewski; Jason A Strelzow; Eugenia Yu; Greg Bondy
Journal:  Int J Cardiol       Date:  2006-07-07       Impact factor: 4.164

5.  Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease.

Authors:  Martin Magnusson; Olle Melander; Bo Israelsson; Anders Grubb; Leif Groop; Stefan Jovinge
Journal:  Diabetes Care       Date:  2004-08       Impact factor: 19.112

6.  Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes.

Authors:  Donna H Ryan; Mark A Espeland; Gary D Foster; Steven M Haffner; Van S Hubbard; Karen C Johnson; Steven E Kahn; William C Knowler; Susan Z Yanovski
Journal:  Control Clin Trials       Date:  2003-10

7.  Impact of obesity on plasma natriuretic peptide levels.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Peter W F Wilson; Ramachandran S Vasan
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

8.  Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial.

Authors:  Xavier Pi-Sunyer; George Blackburn; Frederick L Brancati; George A Bray; Renee Bright; Jeanne M Clark; Jeffrey M Curtis; Mark A Espeland; John P Foreyt; Kathryn Graves; Steven M Haffner; Barbara Harrison; James O Hill; Edward S Horton; John Jakicic; Robert W Jeffery; Karen C Johnson; Steven Kahn; David E Kelley; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Brenda Montgomery; David M Nathan; Jennifer Patricio; Anne Peters; J Bruce Redmon; Rebecca S Reeves; Donna H Ryan; Monika Safford; Brent Van Dorsten; Thomas A Wadden; Lynne Wagenknecht; Jacqueline Wesche-Thobaben; Rena R Wing; Susan Z Yanovski
Journal:  Diabetes Care       Date:  2007-03-15       Impact factor: 19.112

9.  Altered body composition in type 2 diabetes mellitus.

Authors:  S Heshka; A Ruggiero; G A Bray; J Foreyt; S E Kahn; C E Lewis; M Saad; A V Schwartz
Journal:  Int J Obes (Lond)       Date:  2008-01-29       Impact factor: 5.095

10.  The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women.

Authors:  M N Harvie; M Pegington; M P Mattson; J Frystyk; B Dillon; G Evans; J Cuzick; S A Jebb; B Martin; R G Cutler; T G Son; S Maudsley; O D Carlson; J M Egan; A Flyvbjerg; A Howell
Journal:  Int J Obes (Lond)       Date:  2010-10-05       Impact factor: 5.095

View more
  10 in total

Review 1.  The pathophysiology of heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

Review 2.  Mechanisms of heart failure in obesity.

Authors:  Imo A Ebong; David C Goff; Carlos J Rodriguez; Haiying Chen; Alain G Bertoni
Journal:  Obes Res Clin Pract       Date:  2014-01-06       Impact factor: 2.288

3.  Association of menopause age and N-terminal pro brain natriuretic peptide: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Imo A Ebong; Karol E Watson; David C Goff; David A Bluemke; Preethi Srikanthan; Tamara Horwich; Alain G Bertoni
Journal:  Menopause       Date:  2015-05       Impact factor: 2.953

Review 4.  Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

Authors:  Craig A Johnston; Jennette P Moreno; John P Foreyt
Journal:  Curr Atheroscler Rep       Date:  2014-12       Impact factor: 5.113

5.  Lack of association between chronic exposure to biomass fuel smoke and markers of right ventricular pressure overload at high altitude.

Authors:  Maria A Caravedo; Matthew S Painschab; Victor G Davila-Roman; Aldo De Ferrari; Robert H Gilman; Angel D Vasquez-Villar; Suzanne L Pollard; J Jaime Miranda; William Checkley
Journal:  Am Heart J       Date:  2014-07-24       Impact factor: 4.749

Review 6.  INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist.

Authors:  Hugo R Ramos; Andreas L Birkenfeld; Adolfo J de Bold
Journal:  Endocr Connect       Date:  2015-09       Impact factor: 3.335

7.  NTproBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato Study.

Authors:  Stefano Baldassarre; Salvatore Fragapani; Antonio Panero; Debora Fedele; Silvia Pinach; Manuela Lucchiari; Anna Rita Vitale; Giulio Mengozzi; Gabriella Gruden; Graziella Bruno
Journal:  Cardiovasc Diabetol       Date:  2017-09-25       Impact factor: 9.951

8.  Weight loss in heart failure is associated with increased mortality only in non-obese patients without diabetes.

Authors:  Jacek T Niedziela; Bartosz Hudzik; Krzysztof Strojek; Lech Poloński; Mariusz Gąsior; Piotr Rozentryt
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-08-09       Impact factor: 12.910

9.  Inverse association of N-terminal pro-B-type natriuretic peptide with metabolic syndrome in patients with congestive heart failure.

Authors:  Huai-Ren Chang; Jen-Che Hsieh; Bang-Gee Hsu; Ling-Yi Wang; Michael Yu-Chih Chen; Ji-Hung Wang
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

10.  The effect of surgical and non-surgical weight loss on N-terminal pro-B-type natriuretic peptide and its relation to obstructive sleep apnea and pulmonary function.

Authors:  Anne-Marie Gabrielsen; Torbjørn Omland; Mette Brokner; Jan Magnus Fredheim; Jens Jordan; Sverre Lehmann; May Brit Lund; Jøran Hjelmesæth; Dag Hofsø
Journal:  BMC Res Notes       Date:  2016-09-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.